Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
Google Secures Pentagon AI Deal for Classified Projects 
SAN DIEGO, Feb. 08, 2016 -- SENTÉ, a privately held specialty aesthetics company pioneering the development of differentiated medical grade skincare products based on the science of glycosaminoglycans, today announced the close of a $5 million financing. This financing included both existing and new individual investors and provides SENTÉ with a sizable cash balance to fuel expansion and continued company growth.
“We are very pleased to continue seeing such strong investor interest in our company from leading experts in the healthcare and aesthetic field,” said Kleanthis G. Xanthopoulos, Ph.D., SENTÉ Co-Founder and Board Member. “Our investors share our vision in creating unique science based dermatological products that will have profound impacts on the skin, and we very much look forward to continued growth in this endeavor."
The Company, which realized top line year over year growth of 266%, will use this financing to increase its domestic sales force, support the launch of new and innovative products, pursue international expansion and invest behind meaningful new technologies.
“We are excited about the significant progress SENTÉ made in 2015 and we are equally pleased with the continued financial support of our investors,” said Faheem Hasnain, Chairman of the Board of SENTÉ. “We look forward to an exciting year in 2016 with continued strong revenue growth.”
About SENTÉ:
SENTÉ is a privately held specialty aesthetics company leveraging its expertise and foundation in biotechnology to deliver novel, science-based skin care products. SENTÉ is a recognized leader in the development of innovative and targeted medical skincare products based on glycosaminoglycans. Founded in 2007 and based in San Diego, California, further information may be found at http://sentelabs.com/. SENTÉ products are available through our exclusive network of physicians and medically supervised spas.
Financial Contact: Michael Brower Chief Financial Officer [email protected] p: 760.478.3603 Media Contact: Creative Media Marketing Danielle Hale [email protected] p: 212.979.8884 ext. 213
